TOUGH ON CANCER, NOT ON PATIENTS. Gibson acquired the Indenos and has worked for several years with experts at the NIH and Purdue University to provide a positive impact on cancer patients’ lives. Firstly, to combat cancer resistance in patients with certain biomarkers, and secondly by achieving high tumor concentrations with less toxicity for children and adults. This has been an evolving field, with Gibson recently acquiring the Azaindenoisoquinolines (Aza’s) which is Gibson’s approach to offering a drug for the ‘undruggable’ problem of cMyc induced cancers. In addition, the FluorIndenos which when combined with antibodies offer targeted antibody warheads as an immunologic approach to cancer therapy.